Completed PHASE1 INTERVENTIONAL 2-arm NCT02316730

A Bioequivalence Study of Sanchi-Tongshu Capsule (Enteric Coated Pellets)

Single-dose, Open, Randomized, Two-period, Crossover Comparative Bioavailability Study of Sanchi-Tongshu Capsule and Sanchi-Tongshu Capsule (Enteric Coated Pellets) in Chinese Healthy Adult Male Subjects

Sponsor: Pharmaceutical Factory of Chengdu HuaSun Group Inc., Ltd.

Conditions Healthy

Interventions Sanchi-Tongshu Capsule Sanchi-Tongshu Capsule (Enteric coated pellets)

Updated 5 times since 2017 Last updated: Apr 30, 2015 Started: Jun 30, 2014 Primary completion: Jul 31, 2014 Completion: Dec 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Healthy, this trial is completed. The trial is conducted by Pharmaceutical Factory of Chengdu HuaSun Group Inc., Ltd. and has accumulated 5 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Jun 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pharmaceutical Factory of Chengdu HuaSun Group Inc., Ltd.
Sichuan University
West China Second University Hospital

Data source: Pharmaceutical Factory of Chengdu HuaSun Group Inc., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chengdu, China